4.3 Article

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma

Journal

ONCOTARGET
Volume 8, Issue 47, Pages 81794-81802

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.20864

Keywords

DLBCL; PI3K; Idelalisib; ABC DLBCL; BYL719

Funding

  1. National Institutes of Health, National Cancer Institute

Ask authors/readers for more resources

Cell line models of the activated B cell-like (ABC) subtype of diffuse large B cell (DLBCL) depend on both NF-kappa B and phosphatidylinositol 3-kinase (PI3K) signaling pathways for survival, especially those with gain-of-function B cell receptor (BCR) mutations. Here we show that these cells depend specifically on the PI3K delta isoform, but that PI3K pathway interruption by PI3K delta inhibitors is short-lived due to feedback activation of the PI3K alpha isoform. PI3K delta and PI3K alpha inhibition cooperated in killing ABC DLBCL lines, and genetic knockdown of PI3K alpha sensitized cells to PI3K delta inhibition and prolonged the interruption of PI3K signaling. PI3K delta inhibition evoked feedback activation of proximal BCR signaling, which increased the association of PI3K alpha with BCAP and CD19 and increased overall PI3K activity. These results support the clinical evaluation of dual PI3K delta and PI3K alpha inhibition in patients with ABC DLBCL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells

Massimo Fantini, Justin M. David, Hing C. Wong, Christina M. Annunziata, Philip M. Arlen, Kwong Y. Tsang

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2019)

Article Medicine, Research & Experimental

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use

Daniel S. Green, Ana T. Nunes, Kevin W. Tosh, Virginia David-Ocampo, Vicki S. Fellowes, Jiaqiang Ren, Jianjian Jin, Sue-Ellen Frodigh, Chauha Pham, Jolynn Procter, Celina Tran, Irene Ekwede, Hanh Khuu, David F. Stroncek, Steven L. Highfill, Kathryn C. Zoon, Christina M. Annunziata

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

Article Oncology

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial

Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika P. Hamilton, Christina M. Annunziata, Hans Juergen Grote, Anja von Heydebreck, Jaspreet Grewal, Vikram Chand, James L. Gulley

JAMA ONCOLOGY (2019)

Meeting Abstract Oncology

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

Maria Pia Morelli, Justin M. David, Nicole D. Houston, Stan Lipkowitz, Jung-min Lee, Alexandra Dos Santos Zimmer, Farah Z. Zia, Irene Ekwede, Erin Nichols, Mira Pavelova, Rebecca Trupp, Stephen M. Hewitt, Massimo Fantini, Philip M. Arlen, Kwong Y. Tsang, Christina M. Annunziata

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston, Jung-Min Lee

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Article Oncology

Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course

Jung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, Akira Yuno, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Ursula Matulonis, Lauren A. MacDonald, Jayakumar R. Nair, Kimberley M. Macneill, Jane B. Trepel

ONCOLOGY LETTERS (2019)

Review Oncology

NF-κB Signaling in Ovarian Cancer

Brittney S. Harrington, Christina M. Annunziata

CANCERS (2019)

Article Oncology

Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer

Anne M. Noonan, Amanda Cousins, David Anderson, Kristen P. Zeligs, Kristen Bunch, Lidia Hernandez, Yusuke Shibuya, Ian S. Goldlust, Rajarshi Guha, Marc Ferrer, Craig J. Thomas, Christina M. Annunziata

CANCERS (2020)

Editorial Material Oncology

Prenatal DNA Sequencing for Fetal Aneuploidy Also Detects Maternal Cancer: Importance of Timely Workup and Management in Pregnant Women

Amy E. Turriff, Christina M. Annunziata, Diana W. Bianchi

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Oncology

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas

Kwong Yok Tsang, Massimo Fantini, Sharon A. Mavroukakis, Anjum Zaki, Christina M. Annunziata, Philip M. Arlen

Summary: This article describes a tumor-targeting monoclonal antibody called NEO-201, which can inhibit tumor growth through multiple mechanisms. NEO-201 kills tumor cells by engaging with immune cells through antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity, and it can also block interactions between tumor cells and other cells to enhance anti-cancer activity.

CANCERS (2022)

Article Oncology

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201

Kwong Y. Tsang, Massimo Fantini, Anjum Zaki, Sharon A. Mavroukakis, Maria Pia Morelli, Christina M. Annunziata, Philip M. Arlen

Summary: Glycosylation is an important post-translational modification that occurs on mammalian proteins and lipids. Disruption of O-glycosylation patterns, especially the truncation of O-glycans, has been observed in cancer cells. Monoclonal antibodies targeting truncated O-glycans in cancer cells can be an effective strategy to counter tumor growth.

CANCERS (2022)

Meeting Abstract Oncology

Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial.

Anna Duemler, Daniel S. Green, Steven L. Highfill, David Stroncek, Kathryn Zoon, Christina M. Annunziata

JOURNAL OF CLINICAL ONCOLOGY (2019)

Meeting Abstract Oncology

Mechanisms of action of a neoantigen-targeting antibody NEO-201

Philip Martin Arlen, Massimo Fantini, Justin David, Christina M. Annunziata, Kwong Y. Tsang, Pia Morelli

CANCER RESEARCH (2019)

Meeting Abstract Oncology

A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Armin Ghobadi, Premal Thaker, David Weng, Julie Vanas, Irene Ekwede, Mira Pavlova, Robert Keefe, Michael Kuo, Claudio Dansky Ullmann, Raffit Hassan, Christina Annunziata

CANCER RESEARCH (2019)

No Data Available